Ozempic and Wegovy Kidney Injury Claims

Acute kidney injury (AKI) is a sudden decline in kidney function. The FDA prescribing information for Ozempic and Wegovy warns about acute kidney injury due to volume depletion and describes postmarketing reports in some patients treated with semaglutide. The current Ozempic label states that many reported events occurred in people whose nausea, vomiting, or diarrhea led to dehydration. This warning identifies a safety concern; it does not establish that semaglutide caused any particular person’s kidney injury.

How severe gastrointestinal symptoms may relate to kidney injury

Kidneys depend on adequate blood flow and fluid balance. Serious vomiting or diarrhea can cause dehydration and may contribute to acute kidney injury, particularly in people with underlying kidney disease or other risk factors. The FDA advises monitoring renal function when a patient reports adverse reactions that could lead to volume depletion. A clinician must evaluate the individual patient, determine the diagnosis, and consider other causes and contributing conditions.

Ozempic and Wegovy contain semaglutide but have different approved indications and dosing. The relevant product, dose, treatment dates, symptoms, laboratory results, medication changes, and medical history all matter. A temporal relationship between taking a medicine and developing AKI is not, by itself, proof of causation.

Possible signs and the importance of medical care

Dehydration and kidney problems can become serious. Reduced urination, persistent vomiting or diarrhea, marked weakness, confusion, or other concerning symptoms should be discussed promptly with a healthcare professional. Seek emergency care for severe symptoms. This website is not a substitute for diagnosis or treatment. Follow your treating clinician’s instructions and do not change prescription medication based only on general information online.

When could an Ozempic or Wegovy kidney-injury case be reviewed?

A person diagnosed with acute kidney injury during or after semaglutide treatment may ask whether the facts warrant legal review. The diagnosis alone does not establish that a drug caused the injury or that a product-liability claim exists. A case-specific review may examine the adequacy of warnings, the known risk of dehydration from gastrointestinal reactions, prescribing and monitoring, alternative causes, and whether the product was a substantial factor under the applicable law.

Relevant information may include:

• Medical records, lab results, hospital records, diagnosis, and treatment course
• Prescription and pharmacy histories, product name, dose, and dates of use
• Records of nausea, vomiting, diarrhea, reduced fluid intake, or dehydration
• Preexisting kidney conditions, other medications, and other possible causes
• Product labeling and safety information in effect during treatment
• Hospital and follow-up costs, lost income, long-term care, and lasting impairment
• Applicable time limits, venue, and procedural rules

Keeping a timeline of medication use, symptoms, medical visits, and test results can assist a review. There is no universal checklist or guaranteed claim outcome. A qualified medical professional should address medical questions and treatment decisions.

Other Ozempic and Wegovy injury pages

Visit our Ozempic and Wegovy injury overview for information about semaglutide products and case review. We also discuss gastroparesis and severe stomach-emptying problems, gallbladder and biliary conditions, vision loss and NAION, and pancreatitis claims. Each condition involves different medical questions and requires an individualized assessment.

How Logue Law Group reviews semaglutide injury matters

Logue Law Group handles Ozempic and Wegovy injury matters and works with leading national mass-tort firms on complex pharmaceutical litigation. We review potential matters individually and explain whether further investigation may be appropriate. No particular result, settlement, or eligibility determination is promised. Contacting the firm does not create an attorney-client relationship; representation begins only after conflicts are checked and a written agreement is signed.

To request a confidential case review, call (412) 387-6901 or use the online contact page. Do not send confidential medical records through an unsecured channel; ask our team about a secure way to provide information.

Frequently asked questions

Does the FDA warning prove Ozempic or Wegovy caused my kidney injury?

No. FDA labeling describes reported events and warns about acute kidney injury due to volume depletion. Whether a medicine contributed to a particular injury depends on medical evidence, other causes, product warnings, and the applicable legal standard.

Can dehydration be part of the analysis?

Yes. The current FDA label describes reported acute kidney injury events, many of which involved gastrointestinal symptoms that led to dehydration. Medical records can help establish what happened in an individual case.

How long do I have to file a claim?

Deadlines vary based on state law, claim type, and individual facts. Ask a lawyer to assess the deadlines that may apply to your situation as soon as practical.

Sources: FDA Ozempic prescribing information; FDA Wegovy prescribing information.

Notice: This page provides general information, not medical advice or a conclusion that anyone has a legal claim. Seek advice from a qualified healthcare professional for medical concerns. Laws and deadlines vary. Prior results do not guarantee a similar outcome.